News | March 29, 2025
Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Positions Curium as leading manufacturer of Lu-177 isotope
The first-of-its-kind study will evaluate potential association between GSK’s shingles vaccine and reduced dementia risk, building on growing body of evidence from observational and retrospective studies
Dr. Benjamin Bechem, already leading WeylChem Organica and European custom manufacturing sales
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
The freshly infused capital will primarily be deployed towards expansion and research & development
Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound pressure waves to treat arterial calcium blockages
This program, titled "Food Supplementation and Capacity Building Support for Improved Nutrition in Malinao, Aklan," aligns with the country’s national health
Subscribe To Our Newsletter & Stay Updated
